15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells

Carl E. Clay, Arta M Monjazeb, Jacqueline Thorburn, Floyd H. Chilton, Kevin P. High

Research output: Contribution to journalArticle

100 Citations (Scopus)

Abstract

Naturally occurring derivatives of arachidonic acid are potent agonists for the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ) and block cancer cell proliferation through the induction of apoptosis. We have previously reported that induction of apoptosis using cyclopentenone prostaglandins of the J series, including 15deoxyΔ12,14PGJ2 (15dPGJ2), is associated with a high degree of PPAR-response element (PPRE) activity and requires early de novo gene expression in breast cancer cells. In the current study, we used pharmacologic and genetic approaches to test the hypothesis that PPARγ is required for 15dPGJ2-induced apoptosis. The PPARγ agonists 15dPGJ2, trogliltazone (TGZ), and GW7845, a synthetic and highly selective tyrosine-based PPARγ agonist, all increased transcriptional activity of PPARγ, and expression of CD36, a PPARγ-dependent gene. Transcriptional activity and CD36 expression was reduced by GW9662, a selective and irreversible PPARγ antagonist, but GW9662 did not block apoptosis induced by 15dPGJ2. Moreover, dominant negative expression of PPARγ blocked PPRE transcriptional activity, but did not block 15dPGJ2-induced apoptosis. These studies show that while 15dPGJ2 activates PPRE-mediated transcription, PPARγ is not required for 15dPGJ2-induced apoptosis in breast cancer cells. Other likely mechanisms through which cyclopentenone prostaglandins induce apoptosis of cancer cells are discussed.

Original languageEnglish (US)
Pages (from-to)1818-1828
Number of pages11
JournalJournal of Lipid Research
Volume43
Issue number11
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

PPAR gamma
Cells
Apoptosis
Breast Neoplasms
Response Elements
Peroxisome Proliferator-Activated Receptors
Prostaglandins
15-deoxy-delta(12,14)-prostaglandin J2
Cell proliferation
Transcription
Cytoplasmic and Nuclear Receptors
Arachidonic Acid
Gene expression
Tyrosine
Neoplasms
Genes
Cell Proliferation
Derivatives
Gene Expression

Keywords

  • Arachidonic acid metabolism
  • Cyclopentenone prostaglandins
  • Peroxisome proliferator-activated receptor γ

ASJC Scopus subject areas

  • Endocrinology

Cite this

15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. / Clay, Carl E.; Monjazeb, Arta M; Thorburn, Jacqueline; Chilton, Floyd H.; High, Kevin P.

In: Journal of Lipid Research, Vol. 43, No. 11, 01.11.2002, p. 1818-1828.

Research output: Contribution to journalArticle

Clay, Carl E. ; Monjazeb, Arta M ; Thorburn, Jacqueline ; Chilton, Floyd H. ; High, Kevin P. / 15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. In: Journal of Lipid Research. 2002 ; Vol. 43, No. 11. pp. 1818-1828.
@article{fdbd70a807af43b88c88fc3a7787eba8,
title = "15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells",
abstract = "Naturally occurring derivatives of arachidonic acid are potent agonists for the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ) and block cancer cell proliferation through the induction of apoptosis. We have previously reported that induction of apoptosis using cyclopentenone prostaglandins of the J series, including 15deoxyΔ12,14PGJ2 (15dPGJ2), is associated with a high degree of PPAR-response element (PPRE) activity and requires early de novo gene expression in breast cancer cells. In the current study, we used pharmacologic and genetic approaches to test the hypothesis that PPARγ is required for 15dPGJ2-induced apoptosis. The PPARγ agonists 15dPGJ2, trogliltazone (TGZ), and GW7845, a synthetic and highly selective tyrosine-based PPARγ agonist, all increased transcriptional activity of PPARγ, and expression of CD36, a PPARγ-dependent gene. Transcriptional activity and CD36 expression was reduced by GW9662, a selective and irreversible PPARγ antagonist, but GW9662 did not block apoptosis induced by 15dPGJ2. Moreover, dominant negative expression of PPARγ blocked PPRE transcriptional activity, but did not block 15dPGJ2-induced apoptosis. These studies show that while 15dPGJ2 activates PPRE-mediated transcription, PPARγ is not required for 15dPGJ2-induced apoptosis in breast cancer cells. Other likely mechanisms through which cyclopentenone prostaglandins induce apoptosis of cancer cells are discussed.",
keywords = "Arachidonic acid metabolism, Cyclopentenone prostaglandins, Peroxisome proliferator-activated receptor γ",
author = "Clay, {Carl E.} and Monjazeb, {Arta M} and Jacqueline Thorburn and Chilton, {Floyd H.} and High, {Kevin P.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1194/jlr.M200224-JLR200",
language = "English (US)",
volume = "43",
pages = "1818--1828",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "11",

}

TY - JOUR

T1 - 15-Deoxy-Δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells

AU - Clay, Carl E.

AU - Monjazeb, Arta M

AU - Thorburn, Jacqueline

AU - Chilton, Floyd H.

AU - High, Kevin P.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Naturally occurring derivatives of arachidonic acid are potent agonists for the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ) and block cancer cell proliferation through the induction of apoptosis. We have previously reported that induction of apoptosis using cyclopentenone prostaglandins of the J series, including 15deoxyΔ12,14PGJ2 (15dPGJ2), is associated with a high degree of PPAR-response element (PPRE) activity and requires early de novo gene expression in breast cancer cells. In the current study, we used pharmacologic and genetic approaches to test the hypothesis that PPARγ is required for 15dPGJ2-induced apoptosis. The PPARγ agonists 15dPGJ2, trogliltazone (TGZ), and GW7845, a synthetic and highly selective tyrosine-based PPARγ agonist, all increased transcriptional activity of PPARγ, and expression of CD36, a PPARγ-dependent gene. Transcriptional activity and CD36 expression was reduced by GW9662, a selective and irreversible PPARγ antagonist, but GW9662 did not block apoptosis induced by 15dPGJ2. Moreover, dominant negative expression of PPARγ blocked PPRE transcriptional activity, but did not block 15dPGJ2-induced apoptosis. These studies show that while 15dPGJ2 activates PPRE-mediated transcription, PPARγ is not required for 15dPGJ2-induced apoptosis in breast cancer cells. Other likely mechanisms through which cyclopentenone prostaglandins induce apoptosis of cancer cells are discussed.

AB - Naturally occurring derivatives of arachidonic acid are potent agonists for the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARγ) and block cancer cell proliferation through the induction of apoptosis. We have previously reported that induction of apoptosis using cyclopentenone prostaglandins of the J series, including 15deoxyΔ12,14PGJ2 (15dPGJ2), is associated with a high degree of PPAR-response element (PPRE) activity and requires early de novo gene expression in breast cancer cells. In the current study, we used pharmacologic and genetic approaches to test the hypothesis that PPARγ is required for 15dPGJ2-induced apoptosis. The PPARγ agonists 15dPGJ2, trogliltazone (TGZ), and GW7845, a synthetic and highly selective tyrosine-based PPARγ agonist, all increased transcriptional activity of PPARγ, and expression of CD36, a PPARγ-dependent gene. Transcriptional activity and CD36 expression was reduced by GW9662, a selective and irreversible PPARγ antagonist, but GW9662 did not block apoptosis induced by 15dPGJ2. Moreover, dominant negative expression of PPARγ blocked PPRE transcriptional activity, but did not block 15dPGJ2-induced apoptosis. These studies show that while 15dPGJ2 activates PPRE-mediated transcription, PPARγ is not required for 15dPGJ2-induced apoptosis in breast cancer cells. Other likely mechanisms through which cyclopentenone prostaglandins induce apoptosis of cancer cells are discussed.

KW - Arachidonic acid metabolism

KW - Cyclopentenone prostaglandins

KW - Peroxisome proliferator-activated receptor γ

UR - http://www.scopus.com/inward/record.url?scp=0036847134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036847134&partnerID=8YFLogxK

U2 - 10.1194/jlr.M200224-JLR200

DO - 10.1194/jlr.M200224-JLR200

M3 - Article

C2 - 12401880

AN - SCOPUS:0036847134

VL - 43

SP - 1818

EP - 1828

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 11

ER -